NO884497L - Dideoksycytidin-derivater. - Google Patents
Dideoksycytidin-derivater.Info
- Publication number
- NO884497L NO884497L NO88884497A NO884497A NO884497L NO 884497 L NO884497 L NO 884497L NO 88884497 A NO88884497 A NO 88884497A NO 884497 A NO884497 A NO 884497A NO 884497 L NO884497 L NO 884497L
- Authority
- NO
- Norway
- Prior art keywords
- dideoxycytidine
- didehydro
- cytidine
- methylene
- dideoxy
- Prior art date
Links
- -1 n-pentadecyl Chemical group 0.000 claims description 75
- 238000000034 method Methods 0.000 claims description 46
- 150000001875 compounds Chemical class 0.000 claims description 45
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 claims description 21
- OOBICGOWICFMIX-POYBYMJQSA-N 4-amino-1-[(2r,5s)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1C=C[C@@H](CO)O1 OOBICGOWICFMIX-POYBYMJQSA-N 0.000 claims description 18
- ZSDHJVYNLVMDBK-GXSJLCMTSA-N n'-[1-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]-n,n-dimethylmethanimidamide Chemical compound O=C1N=C(N=CN(C)C)C=CN1[C@@H]1O[C@H](CO)CC1 ZSDHJVYNLVMDBK-GXSJLCMTSA-N 0.000 claims description 10
- 150000008064 anhydrides Chemical class 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 8
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 150000004820 halides Chemical class 0.000 claims description 5
- HKDAFUPPEOXZKF-JOYOIKCWSA-N n-[1-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]butanamide Chemical compound O=C1N=C(NC(=O)CCC)C=CN1[C@@H]1O[C@H](CO)CC1 HKDAFUPPEOXZKF-JOYOIKCWSA-N 0.000 claims description 5
- LBFZYGWAPSEWPD-CMPLNLGQSA-N [(2s,5r)-5-(4-acetamido-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl acetate Chemical compound O=C1N=C(NC(=O)C)C=CN1[C@@H]1O[C@H](COC(C)=O)CC1 LBFZYGWAPSEWPD-CMPLNLGQSA-N 0.000 claims description 4
- OTQXWAOJVNLBHP-NZQKXSOJSA-N [(2s,5r)-5-[2-oxo-4-[(2-phenylacetyl)amino]pyrimidin-1-yl]oxolan-2-yl]methyl 2-phenylacetate Chemical compound C1=CN([C@@H]2O[C@H](COC(=O)CC=3C=CC=CC=3)CC2)C(=O)N=C1NC(=O)CC1=CC=CC=C1 OTQXWAOJVNLBHP-NZQKXSOJSA-N 0.000 claims description 4
- DSVLRWNHWTXQIA-GXTWGEPZSA-N [(2s,5r)-5-[4-(2-methylpropanoylamino)-2-oxopyrimidin-1-yl]oxolan-2-yl]methyl 2-methylpropanoate Chemical compound O=C1N=C(NC(=O)C(C)C)C=CN1[C@@H]1O[C@H](COC(=O)C(C)C)CC1 DSVLRWNHWTXQIA-GXTWGEPZSA-N 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 239000007858 starting material Substances 0.000 claims description 4
- STCUDLHDTFFXLC-CMPLNLGQSA-N [(2s,5r)-5-(4-acetamido-2-oxopyrimidin-1-yl)-2,5-dihydrofuran-2-yl]methyl acetate Chemical compound O=C1N=C(NC(=O)C)C=CN1[C@H]1C=C[C@@H](COC(C)=O)O1 STCUDLHDTFFXLC-CMPLNLGQSA-N 0.000 claims description 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- DQKYHMYIQTYMQB-XJKSGUPXSA-N n-[1-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]-2-phenylacetamide Chemical compound O1[C@H](CO)CC[C@@H]1N1C(=O)N=C(NC(=O)CC=2C=CC=CC=2)C=C1 DQKYHMYIQTYMQB-XJKSGUPXSA-N 0.000 claims description 3
- ZFDZWMCMWRPWDU-WCBMZHEXSA-N n-[1-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]acetamide Chemical compound O=C1N=C(NC(=O)C)C=CN1[C@@H]1O[C@H](CO)CC1 ZFDZWMCMWRPWDU-WCBMZHEXSA-N 0.000 claims description 3
- YGZQYMMFALYKCO-GXTWGEPZSA-N n-[1-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]benzamide Chemical compound O1[C@H](CO)CC[C@@H]1N1C(=O)N=C(NC(=O)C=2C=CC=CC=2)C=C1 YGZQYMMFALYKCO-GXTWGEPZSA-N 0.000 claims description 3
- PQTVYTMWPWNAQH-XUZZJYLKSA-N n-[1-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]hexadecanamide Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCC)C=CN1[C@@H]1O[C@H](CO)CC1 PQTVYTMWPWNAQH-XUZZJYLKSA-N 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 2
- KWIJGLUWHTWEJE-JOYOIKCWSA-N N-[1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-2-oxopyrimidin-4-yl]butanamide Chemical compound C(CCC)(=O)NC1=NC(N([C@H]2C=C[C@@H](CO)O2)C=C1)=O KWIJGLUWHTWEJE-JOYOIKCWSA-N 0.000 claims description 2
- 206010038997 Retroviral infections Diseases 0.000 claims description 2
- 150000004753 Schiff bases Chemical group 0.000 claims description 2
- TVADEAKTBRDRPV-NZQKXSOJSA-N [(2s,5r)-5-[2-oxo-4-[(2-phenylacetyl)amino]pyrimidin-1-yl]-2,5-dihydrofuran-2-yl]methyl 2-phenylacetate Chemical compound C1=CN([C@H]2C=C[C@@H](COC(=O)CC=3C=CC=CC=3)O2)C(=O)N=C1NC(=O)CC1=CC=CC=C1 TVADEAKTBRDRPV-NZQKXSOJSA-N 0.000 claims description 2
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 125000004185 ester group Chemical group 0.000 claims description 2
- 230000003301 hydrolyzing effect Effects 0.000 claims description 2
- ATWRHZIQCNPLPR-WCBMZHEXSA-N n-[1-[(2r,5s)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-2-oxopyrimidin-4-yl]acetamide Chemical compound O=C1N=C(NC(=O)C)C=CN1[C@H]1C=C[C@@H](CO)O1 ATWRHZIQCNPLPR-WCBMZHEXSA-N 0.000 claims description 2
- PXKQTZQZCJHBQL-GXTWGEPZSA-N n-[1-[(2r,5s)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-2-oxopyrimidin-4-yl]benzamide Chemical compound C1=C[C@@H](CO)O[C@H]1N1C(=O)N=C(NC(=O)C=2C=CC=CC=2)C=C1 PXKQTZQZCJHBQL-GXTWGEPZSA-N 0.000 claims description 2
- RHPWXXVXHHLMAP-GXSJLCMTSA-N n-[1-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]-2-methylpropanamide Chemical compound O=C1N=C(NC(=O)C(C)C)C=CN1[C@@H]1O[C@H](CO)CC1 RHPWXXVXHHLMAP-GXSJLCMTSA-N 0.000 claims description 2
- YRWXHDZZXYPUKU-JYFHCDHNSA-N n-[1-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]octadecanamide Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCC)C=CN1[C@@H]1O[C@H](CO)CC1 YRWXHDZZXYPUKU-JYFHCDHNSA-N 0.000 claims description 2
- QJPQFZQLJJOHRH-GZMMTYOYSA-N n-[1-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]propanamide Chemical compound O=C1N=C(NC(=O)CC)C=CN1[C@@H]1O[C@H](CO)CC1 QJPQFZQLJJOHRH-GZMMTYOYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229940049953 phenylacetate Drugs 0.000 claims description 2
- SWRPLUDUVYGDTH-GZMMTYOYSA-N N-[1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-2-oxopyrimidin-4-yl]propanamide Chemical compound C(CC)(=O)NC1=NC(N([C@H]2C=C[C@@H](CO)O2)C=C1)=O SWRPLUDUVYGDTH-GZMMTYOYSA-N 0.000 claims 1
- CLRLQMPXTGJHKA-GXSJLCMTSA-N n-[1-[(2r,5s)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-2-oxopyrimidin-4-yl]-2-methylpropanamide Chemical compound O=C1N=C(NC(=O)C(C)C)C=CN1[C@H]1C=C[C@@H](CO)O1 CLRLQMPXTGJHKA-GXSJLCMTSA-N 0.000 claims 1
- WNVJMHDHCZJFAD-XJKSGUPXSA-N n-[1-[(2r,5s)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-2-oxopyrimidin-4-yl]-2-phenylacetamide Chemical compound C1=C[C@@H](CO)O[C@H]1N1C(=O)N=C(NC(=O)CC=2C=CC=CC=2)C=C1 WNVJMHDHCZJFAD-XJKSGUPXSA-N 0.000 claims 1
- DMDRNUKLEFZACL-XUZZJYLKSA-N n-[1-[(2r,5s)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-2-oxopyrimidin-4-yl]hexadecanamide Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCC)C=CN1[C@H]1C=C[C@@H](CO)O1 DMDRNUKLEFZACL-XUZZJYLKSA-N 0.000 claims 1
- KHITWKJYBNMLKF-JYFHCDHNSA-N n-[1-[(2r,5s)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-2-oxopyrimidin-4-yl]octadecanamide Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCC)C=CN1[C@H]1C=C[C@@H](CO)O1 KHITWKJYBNMLKF-JYFHCDHNSA-N 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 68
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
- 239000000203 mixture Substances 0.000 description 35
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 34
- 239000000243 solution Substances 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 239000007787 solid Substances 0.000 description 17
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 16
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 239000012456 homogeneous solution Substances 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 239000003054 catalyst Substances 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 238000010898 silica gel chromatography Methods 0.000 description 9
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 8
- GRWIABMEEKERFV-UHFFFAOYSA-N methanol;oxolane Chemical compound OC.C1CCOC1 GRWIABMEEKERFV-UHFFFAOYSA-N 0.000 description 8
- 229960000523 zalcitabine Drugs 0.000 description 8
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 7
- 238000010828 elution Methods 0.000 description 7
- JAUFWTSSYRTLLB-UHFFFAOYSA-N (2-phenylacetyl) 2-phenylacetate Chemical compound C=1C=CC=CC=1CC(=O)OC(=O)CC1=CC=CC=C1 JAUFWTSSYRTLLB-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- NOGFHTGYPKWWRX-UHFFFAOYSA-N 2,2,6,6-tetramethyloxan-4-one Chemical compound CC1(C)CC(=O)CC(C)(C)O1 NOGFHTGYPKWWRX-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- YHASWHZGWUONAO-UHFFFAOYSA-N butanoyl butanoate Chemical compound CCCC(=O)OC(=O)CCC YHASWHZGWUONAO-UHFFFAOYSA-N 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- LSACYLWPPQLVSM-UHFFFAOYSA-N isobutyric acid anhydride Chemical compound CC(C)C(=O)OC(=O)C(C)C LSACYLWPPQLVSM-UHFFFAOYSA-N 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 4
- WVJVHUWVQNLPCR-UHFFFAOYSA-N octadecanoyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(=O)CCCCCCCCCCCCCCCCC WVJVHUWVQNLPCR-UHFFFAOYSA-N 0.000 description 4
- NGEZPLCPKXKLQQ-VOTSOKGWSA-N (e)-4-(3-methoxyphenyl)but-3-en-2-one Chemical compound COC1=CC=CC(\C=C\C(C)=O)=C1 NGEZPLCPKXKLQQ-VOTSOKGWSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- VMZCDNSFRSVYKQ-UHFFFAOYSA-N 2-phenylacetyl chloride Chemical compound ClC(=O)CC1=CC=CC=C1 VMZCDNSFRSVYKQ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 2
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- QMYTXCUSWCFXLY-UHFFFAOYSA-N methanol;triethylazanium;hydroxide Chemical compound [OH-].OC.CC[NH+](CC)CC QMYTXCUSWCFXLY-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- GHQPBDDZGPAVJP-UHFFFAOYSA-N azanium;methanol;hydroxide Chemical compound N.O.OC GHQPBDDZGPAVJP-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000008364 bulk solution Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical class ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- ARBOVOVUTSQWSS-UHFFFAOYSA-N hexadecanoyl chloride Chemical compound CCCCCCCCCCCCCCCC(Cl)=O ARBOVOVUTSQWSS-UHFFFAOYSA-N 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-M isobutyrate Chemical compound CC(C)C([O-])=O KQNPFQTWMSNSAP-UHFFFAOYSA-M 0.000 description 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- WTBAHSZERDXKKZ-UHFFFAOYSA-N octadecanoyl chloride Chemical compound CCCCCCCCCCCCCCCCCC(Cl)=O WTBAHSZERDXKKZ-UHFFFAOYSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10722187A | 1987-10-09 | 1987-10-09 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO884497D0 NO884497D0 (no) | 1988-10-07 |
| NO884497L true NO884497L (no) | 1989-04-10 |
Family
ID=22315505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO88884497A NO884497L (no) | 1987-10-09 | 1988-10-07 | Dideoksycytidin-derivater. |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0311100A3 (fr) |
| JP (1) | JPH01132597A (fr) |
| KR (1) | KR890006624A (fr) |
| AU (1) | AU2355488A (fr) |
| DK (1) | DK564088A (fr) |
| FI (1) | FI884627A (fr) |
| HU (1) | HU201090B (fr) |
| IL (1) | IL87949A0 (fr) |
| MC (1) | MC1982A1 (fr) |
| NO (1) | NO884497L (fr) |
| NZ (1) | NZ226481A (fr) |
| PT (1) | PT88716B (fr) |
| YU (1) | YU187788A (fr) |
| ZA (1) | ZA886890B (fr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223263A (en) * | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
| US6448392B1 (en) | 1985-03-06 | 2002-09-10 | Chimerix, Inc. | Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use |
| NZ223910A (en) * | 1987-03-20 | 1991-02-26 | Bristol Myers Co | 2',3'-dideoxynucleosides, process for their production and intermediates therefor |
| US5631370A (en) * | 1988-01-20 | 1997-05-20 | Regents Of The University Of Minnesota | Optically-active isomers of dideoxycarbocyclic nucleosides |
| US5817638A (en) * | 1988-07-07 | 1998-10-06 | Nexstar Pharmaceuticals, Inc. | Antiviral liponucleosides: treatment of hepatitis B |
| US6252060B1 (en) | 1988-07-07 | 2001-06-26 | Nexstar Pharmaceuticals, Inc. | Antiviral liponucleosides: treatment of hepatitis B |
| US6599887B2 (en) | 1988-07-07 | 2003-07-29 | Chimerix, Inc. | Methods of treating viral infections using antiviral liponucleotides |
| GB8823320D0 (en) * | 1988-10-05 | 1988-11-09 | Nycomed As | Chemical compounds |
| WO1991006554A1 (fr) * | 1989-11-06 | 1991-05-16 | Nycomed As | Derives de nucleosides |
| US5192764A (en) * | 1991-05-30 | 1993-03-09 | Research Foundation Of State Of N.Y. | Pyrazinone n-oxide nucleosides and analogs thereof |
| RU2085557C1 (ru) * | 1991-09-30 | 1997-07-27 | Санкио Компани Лимитед | Производные нуклеозидов пиримидина или их фармацевтически приемлемые соли и способ их получения |
| US6576636B2 (en) | 1996-05-22 | 2003-06-10 | Protarga, Inc. | Method of treating a liver disorder with fatty acid-antiviral agent conjugates |
| EP1042341A1 (fr) * | 1997-11-25 | 2000-10-11 | Protarga Inc. | Compositions d'analogues de nucleosides et utilisation de ces compositions |
| JP4634694B2 (ja) | 2001-03-23 | 2011-02-16 | ルイトポルド・ファーマシューティカルズ・インコーポレーテッド | 脂肪アルコール薬物複合体 |
| WO2002076402A2 (fr) | 2001-03-23 | 2002-10-03 | Protarga, Inc. | Conjugues a base d'amines gras et d'agents pharmaceutiques |
| BR0214944A (pt) * | 2001-12-14 | 2005-06-07 | Pharmasset Ltd | Nucleosìdeos de n4-acilcitosina para o tratamento de infecções virais |
| US9326983B2 (en) | 2013-08-01 | 2016-05-03 | University Of Kentucky Research Foundation | Compositions and methods for treating retinal degradation |
| AU2016225037B2 (en) * | 2015-02-26 | 2021-06-17 | University Of Kentucky Research Foundation | Compositions and methods for treating retinal degradation |
| US11219623B2 (en) | 2015-02-26 | 2022-01-11 | University Of Kentucky Research Foundation | Inflammasome inhibition for the treatment of Parkinson's disease, Alzheimer's disease and multiple sclerosis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5943550B2 (ja) * | 1975-08-29 | 1984-10-23 | 田辺製薬株式会社 | 不飽和ヌクレオシドの製法 |
| NZ216172A (en) * | 1985-05-15 | 1989-08-29 | Wellcome Found | Nucleosides and pharmaceutical compositions |
| AU613026B2 (en) * | 1987-03-24 | 1991-07-25 | Nycomed As | 2',3' dideoxyribofuranoxide derivatives |
| EP0294113A1 (fr) * | 1987-05-29 | 1988-12-07 | The Wellcome Foundation Limited | Nucléosides thérapeutiques |
| US4837311A (en) * | 1987-06-22 | 1989-06-06 | Hoffman-La Roche Inc. | Anti-retroviral compounds |
-
1988
- 1988-09-15 ZA ZA886890A patent/ZA886890B/xx unknown
- 1988-10-06 NZ NZ226481A patent/NZ226481A/xx unknown
- 1988-10-06 IL IL87949A patent/IL87949A0/xx unknown
- 1988-10-07 DK DK564088A patent/DK564088A/da not_active Application Discontinuation
- 1988-10-07 YU YU01877/88A patent/YU187788A/xx unknown
- 1988-10-07 MC MC882009A patent/MC1982A1/fr unknown
- 1988-10-07 PT PT88716A patent/PT88716B/pt not_active IP Right Cessation
- 1988-10-07 AU AU23554/88A patent/AU2355488A/en not_active Abandoned
- 1988-10-07 KR KR1019880013065A patent/KR890006624A/ko not_active Application Discontinuation
- 1988-10-07 HU HU885191A patent/HU201090B/hu not_active IP Right Cessation
- 1988-10-07 FI FI884627A patent/FI884627A/fi not_active IP Right Cessation
- 1988-10-07 EP EP19880116655 patent/EP0311100A3/fr not_active Withdrawn
- 1988-10-07 NO NO88884497A patent/NO884497L/no unknown
- 1988-10-08 JP JP63254668A patent/JPH01132597A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| YU187788A (en) | 1990-04-30 |
| DK564088A (da) | 1989-04-10 |
| HUT47592A (en) | 1989-03-28 |
| EP0311100A3 (fr) | 1990-10-31 |
| HU201090B (en) | 1990-09-28 |
| MC1982A1 (fr) | 1989-11-23 |
| NZ226481A (en) | 1992-01-29 |
| EP0311100A2 (fr) | 1989-04-12 |
| ZA886890B (en) | 1989-05-30 |
| FI884627A0 (fi) | 1988-10-07 |
| IL87949A0 (en) | 1989-03-31 |
| PT88716B (pt) | 1992-12-31 |
| KR890006624A (ko) | 1989-06-14 |
| NO884497D0 (no) | 1988-10-07 |
| AU2355488A (en) | 1989-04-13 |
| FI884627A (fi) | 1989-04-10 |
| DK564088D0 (da) | 1988-10-07 |
| JPH01132597A (ja) | 1989-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO884497L (no) | Dideoksycytidin-derivater. | |
| RU2144027C1 (ru) | Изохинолины, способ их получения и фармацевтическая композиция на их основе | |
| IL128652A (en) | History of adenosine substituted N6 heterocyclic and pharmaceutical preparations containing them | |
| JP2007526291A (ja) | アデノシン受容体アゴニスト | |
| JPH02503312A (ja) | 化学的化合物 | |
| NO144211B (no) | Analogifremgangsmaate til fremstilling av nye tyrosinderivater med farmasoeytisk virkning paa glatte muskler | |
| WO2023025319A1 (fr) | Nouveau dérivé de cytidine et composition pharmaceutique et utilisation associées | |
| JPS6229566A (ja) | 新規グアニジノメチル安息香酸誘導体 | |
| DK149773B (da) | Analogifremgangsmaade til fremstilling af 3-quinolincarboxylsyrederivater | |
| US4315920A (en) | Adenosine deaminase inhibitors | |
| CN113087713B (zh) | 一类苯并二氮䓬衍生物及其制备方法和用途 | |
| LT3548B (en) | Novel esters, method for the preparation thereof and pharmaceutical composition | |
| CN115135646A (zh) | 取代的多环化合物及其药物组合物和用途 | |
| JPH02124884A (ja) | Ｎ―置換アミド誘導体 | |
| US3956277A (en) | Purine sugar derivatives | |
| JP3885900B2 (ja) | ベンゾピラン誘導体及びそれを有効成分とする心臓疾患治療剤 | |
| PT100216B (pt) | N-{{4,5-di-hidroxi- e 4,5,8-tri-hidroxi-9,10-di-hidro-9,10-dioxo-2-antracentil} carbonil}-aminoacidos uteis na terapia de afeccoes osteoarticulares, processo para a sua preparacao e composicoes farmaceuticas que os contem | |
| HU180617B (en) | Process for producing 1,2-bis-bracket-nicotinamido-bracket closed-propane,salts and pharmaceutical compositions containing them | |
| US4086416A (en) | Septacidin analogs | |
| US4539402A (en) | Quinazolinone derivatives | |
| SK146096A3 (en) | Adenosine derivatives, processes for their preparation, their use for the preparation of drugs, their use in therapy and pharmaceutical compositions containing them | |
| CN115505021B (zh) | 具有炎症性肠病治疗作用的乌苏酸衍生物及其制备方法和用途 | |
| KR870001935B1 (ko) | 항포진성을 갖는 뉴클레오시 유도체 및 그의 산부가염의 제조방법 | |
| US4992446A (en) | Tricyclic quinolizine amides | |
| US4766148A (en) | Biphenylylpropionic acid derivative and pharmaceutical composition containing the same |